TCOV
KRYS icon

Trust Company of Vermont’s Krystal Biotech KRYS Stock Holding History

Trust Company of Vermont’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.93K Hold
20
– – ﹤0.01% 942
2025
Q3 		$3.53K Hold
20
– – ﹤0.01% 965
2025
Q2 		$2.75K Hold
20
– – ﹤0.01% 980
2025
Q1 		$3.61K Hold
20
– – ﹤0.01% 890
2024
Q4 		$3.13K Buy
+20
New +$3.55K ﹤0.01% 913

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trust Company of Vermont's KRYS Position: Q4 2025 in Review

Trust Company of Vermont held its Krystal Biotech (KRYS) position steady in Q4 2025 at 20 shares worth $4.93K. The position accounts for ﹤0.01% of the portfolio, ranked #942.

Trust Company of Vermont first reported a position in KRYS in Q4 2024 and has held it in 5 quarters since. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • Trust Company of Vermont held 20 shares of Krystal Biotech worth $4.93K as of Q4 2025.
  • Trust Company of Vermont left its Krystal Biotech share count unchanged in Q4 2025.
  • Krystal Biotech made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #942 holding.
  • Trust Company of Vermont first reported a position in Krystal Biotech in Q4 2024 and has held it in 5 quarters since.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.